Literature DB >> 28643957

Effectiveness of levetiracetam in an acetazolamide-unresponsive patient with episodic ataxia type 2 by a novel CACNA1A nonsense mutation.

H Lee1, D-H Jang2, J-H Jang3, T Kim4.   

Abstract

Entities:  

Keywords:  episodic ataxia type 2; levetiracetam

Year:  2017        PMID： 28643957     DOI： 10.1111/ene.13327

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  4 in total

1.  The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2.

Authors:  Cristina González-Mingot; Ricard López-Ortega; Luis Brieva-Ruiz
Journal:  Neurol Sci       Date:  2022-05-20       Impact factor: 3.830

2.  Efficacy of levetiracetam in patients with episodic ataxia type 2 caused by CACNA1A mutation: three case reports.

Authors:  Seunghee Na; Taewon Kim
Journal:  Neurol Sci       Date:  2021-06-03       Impact factor: 3.307

Review 3.  Clinical and Genetic Overview of Paroxysmal Movement Disorders and Episodic Ataxias.

Authors:  Giacomo Garone; Alessandro Capuano; Lorena Travaglini; Federica Graziola; Fabrizia Stregapede; Ginevra Zanni; Federico Vigevano; Enrico Bertini; Francesco Nicita
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 5.923

4.  Usefulness of comprehensive targeted multigene panel sequencing for neuromuscular disorders in Korean patients.

Authors:  Jihye Park; Hyun Mi Oh; Hye Jung Park; Ah-Ra Cho; Dong-Woo Lee; Ja-Hyun Jang; Dae-Hyun Jang
Journal:  Mol Genet Genomic Med       Date:  2019-09-01       Impact factor: 2.183
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.